Epigallocatechin gallate inhibits ovarian cancer cell growth and induces cell apoptosis via activation of FOXO3A

被引：5

作者：

Zhang, Zhe ^{[1
]}

Zhang, Qinghua ^{[1
]}

Yu, Yani ^{[1
]}

Su, Shan ^{[1
]}

机构：

[1] Zibo Cent Hosp, Dept Gynecol, 54 Gongqingtuan West Rd, Zibo 255036, Shandong, Peoples R China

来源：

IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL | 2023年 / 59卷 / 10期

关键词：

EGCG; Ovarian cancer; Cell apoptosis; FOXO3A; c-Myc; GREEN TEA; 1ST-LINE TREATMENT; CYCLE ARREST; EGCG; PROLIFERATION; INFLAMMATION; POLYPHENOL; ROLES;

D O I：

10.1007/s11626-023-00830-x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Epigallocatechin gallate (EGCG), a bioactive component in tea, displays broad anti-cancer effects. Our study was designed to evaluate the anti-cancer effects of EGCG on ovarian cancer and explored the underlying molecular mechanisms. To evaluate the in vitro inhibitory effects of EGCG against ovarian cancer, MTT assay, colony formation assay, apoptosis assay, and wound healing assay, were performed. Besides, the inhibitory effects of EGCG on tumor growth in the xenograft animal model were evaluated by measuring tumor volume and tumor weight. Moreover, Western blotting and qPCR were used to evaluate the levels of target genes and proteins. Treatment with EGCG inhibited cell migration and cell survival, and promoted cell apoptosis in A2780 and SKOV3 cells. Interestingly, treatment with EGCG inhibited the tumor growth in the xenograft animal model. The mechanistic study revealed that treatment with EGCG induced the activation of FOXO3A and suppressed the expression of c-Myc both in vitro and in vivo. Our findings demonstrate that EGCG suppress ovarian cancer cell growth, which may be due to its regulation on FOXO3A and c-Myc.

引用

页码：739 / 746

页数：8

共 41 条

[11] Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases [J].

Eng, Qian Yi ;

Thanikachalam, Punniyakoti Veeraveedu ;

Ramamurthy, Srinivasan .

JOURNAL OF ETHNOPHARMACOLOGY, 2018, 210 :296-310

[12] Low expression of Foxo3a is Associated with Poor Prognosis in Ovarian Cancer Patients [J].

Fei, Min ;

Zhao, Yueming ;

Wang, Yuchan ;

Lu, Mudan ;

Cheng, Chun ;

Huang, Xiaodong ;

Zhang, Dongmei ;

Lu, Jianxin ;

He, Song ;

Shen, Aiguo .

CANCER INVESTIGATION, 2009, 27 (01) :52-59

[13] Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review [J].

Gan, Ren-You ;

Li, Hua-Bin ;

Sui, Zhong-Quan ;

Corke, Harold .

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2018, 58 (06) :924-941

[14] Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines [J].

Huh, SW ;

Bae, SM ;

Kim, YW ;

Lee, JM ;

Namkoong, SE ;

Lee, IP ;

Kim, SH ;

Kim, CK ;

Ahn, WS .

GYNECOLOGIC ONCOLOGY, 2004, 94 (03) :760-768

[15] Why drinking green tea could prevent cancer [J].

Jankun, J ;

Selman, SH ;

Swiercz, R ;

SkrzypczakJankun, E .

NATURE, 1997, 387 (6633) :561-561

[16] Ovarian cancer [J].

Jayson, Gordon C. ;

Kohn, Elise C. ;

Kitchener, Henry C. ;

Ledermann, Jonathan A. .

LANCET, 2014, 384 (9951) :1376-1388

[17]

Katoh M, 2004, INT J ONCOL, V25, P1495

[18] FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis [J].

Levanon, K. ;

Sapoznik, S. ;

Bahar-Shany, K. ;

Brand, H. ;

Shapira-Frommer, R. ;

Korach, J. ;

Hirsch, M. S. ;

Roh, M. H. ;

Miron, A. ;

Liu, J. F. ;

Vena, N. ;

Ligon, A. H. ;

Fotheringham, S. ;

Bailey, D. ;

Flavin, R. J. ;

Birrer, M. J. ;

Drapkin, R. I. .

ONCOGENE, 2014, 33 (35) :4424-4432

[19] Critical role of FOXO3a in carcinogenesis [J].

Liu, Ying ;

Ao, Xiang ;

Ding, Wei ;

Ponnusamy, Murugavel ;

Wu, Wei ;

Hao, Xiaodan ;

Yu, Wanpeng ;

Wang, Yifei ;

Li, Peifeng ;

Wang, Jianxun .

MOLECULAR CANCER, 2018, 17

[20]

Luo Ke-Wang, 2018, Oncotarget, V9, P12261, DOI 10.18632/oncotarget.24301

← 1 2 3 4 5 →